ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International, India's leading Contract Research, Development and Manufacturing OrganizationSyngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners.  DUBLIN, Oct.

ERS Genomics Limited（'ERS'）与印度领先的合同研究，开发和制造组织Syngene International完成许可协议Syngene获得ERS Genomics的基础CRISPR/Cas9专利组合，为印度开创了技术创新的新时代全球合作伙伴。都柏林，10月。

18, 2023 /PRNewswire/ -- ERS Genomics, co-founded by Dr. Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on CRISPR/Cas9, provides access to the definitive patent portfolio for this groundbreaking technology.Syngene International Limited, an integrated research, development and manufacturing services company, is poised to leverage the immense potential of CRISPR/Cas9 in various scientific disciplines, including drug discovery, biotechnology, and genomics on behalf of its clients..

182023/PRNewswire/-ERS Genomics由Emmanuelle Charpentier博士共同创立，该博士因其在CRISPR/Cas9方面的开创性工作而获得2020年诺贝尔化学奖，为这一突破性技术提供了明确的专利组合。Syngene International Limited是一家综合研究，开发和制造服务公司，准备代表其客户利用CRISPR/Cas9在各种科学学科（包括药物发现，生物技术和基因组学）方面的巨大潜力。。

Continue Reading

继续阅读

Eric Rhodes, CEO ERS Genomics (PRNewsfoto/ERS Genomics)

Eric Rhodes，首席执行官ERS Genomics（PRNewsfoto/ERS Genomics）

ERS Genomics Logo (PRNewsfoto/ERS Genomics)

ERS Genomics徽标（PRNewsfoto/ERS Genomics）

Eric Rhodes, CEO of ERS Genomics, expressed his enthusiasm, stating, 'We are delighted to partner with Syngene, a global leader in research development and manufacturing services, to empower their scientific endeavours with the transformative capabilities of CRISPR/Cas9. This collaboration promises to unlock new frontiers in genomics research and therapeutic development.'.

ERS Genomics首席执行官Eric Rhodes表示了他的热情，他说：“我们很高兴与研究开发和制造服务领域的全球领导者Syngene合作，以增强他们在CRISPR/Cas9变革能力方面的科学努力。这项合作有望为基因组学研究和治疗开发开辟新的前沿。

Mahesh Bhalgat, Chief Operating Officer, Syngene International Limited, said, 'Syngene is committed to delivering innovative solutions to our partners worldwide. Our agreement with ERS Genomics underscores this commitment, as we gain access to the most advanced CRISPR/Cas9 technology available. This partnership aligns perfectly with our mission to partner with clients to accelerate scientific discovery and support the development of life-changing therapies.'The collaboration between ERS Genomics and Syngene marks a significant addition to India's scientific and commercial landscape and reinforces the nation's growing influence in the global biotechnology and life sciences sector.

Syngene International Limited首席运营官Mahesh Bhalgat表示，“Syngene致力于为全球合作伙伴提供创新的解决方案。我们与ERS Genomics的协议强调了这一承诺，因为我们可以使用最先进的CRISPR/Cas9技术。这种合作关系完全符合我们与客户合作加速科学发现和支持改变生活疗法发展的使命ERS Genomics和Syngene之间的合作标志着印度科学和商业领域的重要补充，并增强了该国在全球生物技术和生命科学领域日益增长的影响力。

Both organizations are focused on driving scientific progress and bringing transformative innovations to the forefront of research and development.About ERS GenomicsERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr.

这两个组织都致力于推动科学进步，并将变革性创新带到研究和发展的前沿。关于ERS GenomicsERS Genomics是一家位于爱尔兰都柏林的生物技术公司。该公司的成立旨在为博士持有的基础CRISPR/Cas9知识产权提供广泛的访问权限。

Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology.

Emmanuelle Charpentier。非独家许可证可用于研究和销售多个领域的产品和服务，包括研究工具，试剂盒，试剂；发现治疗干预的新靶点；用于发现和筛选新候选药物的细胞系；GMP生产保健品；伴侣动物和牲畜健康；生产工业材料，如酶，生物燃料和化学品；和合成生物学。

ERS holds over 100 patents worldwide.For additional information, please visit www.ersgenomics.comMedia contact: Dara O'Donnell - dara.odonnell@ersgenomics.comJanani.Kalyanakrishnan@syngeneintl.com[email protected] About SyngeneSyngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R.

ERS在全球拥有100多项专利。欲了解更多信息，请访问www.ersgenomics.comMedia联系人：Dara O'Donnell-dara.odonnell@ersgenomics.comJanani.Kalyanakrishnan@syngeneintl.com[电子邮件保护]关于SyngeneSyngene International Ltd.（BSE:539268，NSE:SYNGENE，ISIN:INE398R。